Taysha Gene Therapies, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Taysha Gene Therapies reports positive clinical data for TSHA-102 in Rett syndrome, progresses pivotal trials, and extends its cash runway into 2028 through recent capital raises.
NASDAQ
Taysha Gene Therapies' 2024 10-K filing details the company's financial performance and clinical advancements, particularly in its TSHA-102 program for Rett syndrome.
NASDAQ
Taysha Gene Therapies' annual 10-K filing highlights its focus on Rett syndrome treatment with TSHA-102, while discontinuing the TSHA-120 program for GAN and seeking strategic options for other pipeline assets.